Cochrane · systematic review · CD012160
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
Roncolato, F, Lindemann, K, Willson, ML, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
9
No studies
1
Included studies
NR
No studies 1 · 10%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 80%Moderate 1 · 10%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
mTOR inhibitors compared to chemotherapy/hormone therapy for advanced or recurrent endometrial cancer
Population: women with advanced or recurrent endometrial cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression‐free survival: first‐line trials ( mTOR inhibitors vs chemotherapy/hormone therapy | HR 1.43 [1.06, 1.93] | 1 study · 231 participants | Low Downgraded: risk of bias, imprecision |
Progression‐free survival: second/third‐line trials ( mTOR inhibitors vs chemotherapy/hormone therapy | HR 0.53 [0.31, 0.91] | 1 study · 95 participants | Moderate Downgraded: imprecision |
Haematological toxicities ‐ Anaemia mTOR inhibitors vs chemotherapy/hormone therapy | RR 1.42 [0.83, 2.44] | 2 studies · 357 participants | Low Downgraded: imprecision |
Skin toxicities ‐ Mucositis mTOR inhibitors vs chemotherapy/hormone therapy | RR 10.42 [1.34, 80.74] | 2 studies · 357 participants | Low Downgraded: imprecision |
Respiratory toxicity ‐ Interstitial pneumonitis mTOR inhibitors vs chemotherapy/hormone therapy | RR 7.36 [0.88, 61.52] | 2 studies · 357 participants | Low Downgraded: imprecision |
Overall survival: first‐line trials ( mTOR inhibitors vs chemotherapy/hormone therapy | HR 1.32 [0.98, 1.78] | 1 study · 231 participants | Low Downgraded: imprecision |
Overall survival: second/third‐line trials ( mTOR inhibitors vs chemotherapy/hormone therapy | HR 1.06 [0.7, 1.61] | 1 study · 130 participants | Low Downgraded: imprecision |
Objective response rate: first‐line trial mTOR inhibitors vs chemotherapy/hormone therapy | RR 0.93 [0.75, 1.17] | 1 study · 231 participants | Low Downgraded: risk of bias, imprecision |
Objective response rate: second/third‐line trials mTOR inhibitors vs chemotherapy/hormone therapy | RR 0.22 [0.01, 4.4] | 1 study · 61 participants | Low Downgraded: risk of bias, imprecision |
Quality of life ‐ not reported mTOR inhibitors vs chemotherapy/hormone therapy | no estimate extracted | NR | No studies |